Jefferies Financial Group Inc. Acquires Shares of 59,000 DENTSPLY SIRONA Inc. $XRAY

Jefferies Financial Group Inc. acquired a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the third quarter, HoldingsChannel.com reports. The fund acquired 59,000 shares of the medical instruments supplier’s stock, valued at approximately $749,000.

Other hedge funds have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of DENTSPLY SIRONA during the 1st quarter valued at about $26,000. Parkside Financial Bank & Trust raised its holdings in DENTSPLY SIRONA by 620.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 1,477 shares during the period. Huntington National Bank boosted its position in DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,077 shares in the last quarter. True Wealth Design LLC grew its holdings in DENTSPLY SIRONA by 49.7% in the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 1,181 shares during the period. Finally, Central Pacific Bank Trust Division grew its holdings in DENTSPLY SIRONA by 100.0% in the third quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 2,000 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY opened at $11.80 on Friday. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The business’s 50 day moving average price is $12.72 and its 200-day moving average price is $12.43. The firm has a market capitalization of $2.36 billion, a PE ratio of -3.93, a P/E/G ratio of 1.49 and a beta of 0.97. DENTSPLY SIRONA Inc. has a 1 year low of $9.85 and a 1 year high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts expect that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director James D. Forbes bought 5,000 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 9th. The stock was acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $124,800. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gregory T. Lucier purchased 15,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was acquired at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the purchase, the director owned 65,000 shares of the company’s stock, valued at approximately $809,250. This represents a 30.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 70,000 shares of company stock valued at $956,437 in the last ninety days. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

XRAY has been the subject of several research analyst reports. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their target price for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. Barclays began coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price target for the company. Mizuho upped their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Monday, March 2nd. Finally, Robert W. Baird lifted their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Three research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $14.42.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.